Literature DB >> 4026884

Suppression of rheumatoid factor synthesis by antiidiotypic antibody in rheumatoid arthritis patients with cross-reactive idiotypes.

T Takeuchi, O Hosono, J Koide, M Homma, T Abe.   

Abstract

The effect of antiidiotypic antibody on the in vitro production of rheumatoid factor was studied in rheumatoid arthritis patients with cross-reactive idiotypic determinants. Antiidiotypic antibodies (ascites IgG) were developed against monoclonal rheumatoid factor (Ka m-RF) by a cell fusion procedure. These antibodies were idiotype-specific, since: 1) they reacted only with F(ab')2 fragment of Ka m-RF; 2) they failed to react with normal IgM without rheumatoid factor activity; and 3) their F(ab')2 fragment inhibited the rheumatoid factor activity of Ka m-RF. The antiidiotypic antibody strongly suppressed the in vitro production of rheumatoid factor by lymphocytes from unrelated rheumatoid arthritis patients with cross-reactive idiotypes. The suppression was specific, since ascites IgG failed to suppress in vitro anti-keyhole limpet hemocyanin antibody production by the lymphocytes. These results indicate that antiidiotypic antibody may influence the regulation of rheumatoid factor production in patients with rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026884     DOI: 10.1002/art.1780280806

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

Review 1.  The idiotype-antiidiotype network in human autoimmunity.

Authors:  N I Abdou
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

Review 2.  Premises for immune interventional therapy in rheumatoid arthritis.

Authors:  I R Mackay; M J Rowley
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

3.  Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

Authors:  N Harata; T Sasaki; H Osaki; T Saito; S Shibata; T Muryoi; O Takai; K Yoshinaga
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

4.  Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies.

Authors:  A Ruiz-Arguelles
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

5.  Activated T lymphocytes, rheumatoid factor and erythrocyte sedimentation rate assays in rheumatoid arthritis.

Authors:  H Bartfeld; C Dham
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  Suppression of anti-DNA antibody synthesis in vitro by a cross-reactive antiidiotypic antibody.

Authors:  A Epstein; M Greenberg; B Diamond; A I Grayzel
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

7.  In vitro T-cell functions specific to an anti-DNA idiotype and serological markers in patients with systemic lupus erythematosus (SLE).

Authors:  S Mendlovic; Y Shoenfeld; R Bakimer; R Segal; M Dayan; E Mozes
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

Review 8.  Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases.

Authors:  Shing Yi Pan; Yvonne Cashinn Chia; Hui Rong Yee; Angelina Ying Fang Cheng; Clarice Evey Anjum; Yenny Kenisi; Mike Ks Chan; Michelle Bf Wong
Journal:  Future Sci OA       Date:  2020-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.